Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASCEND; ASCEND in SPMS
  • Sponsors Biogen

    • Most Recent Events

    • 01 Dec 2022 Results assessing the sensitivity and clinical meaningfulness of ODRS using natalizumab Phase 3 data sets -AFFIRM in relapsing-remitting MS and ASCEND in secondary progressive MS, published in the Multiple Sclerosis Journal
    • 09 Nov 2022 Results (from studies EXPAND and ASCEND) assessing Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 28 Oct 2022 Results analyzing longitudinal sGFAP and clinical outcome data, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top